![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Zuurhout Miranda JL Vijverberg Susanne JH Raaijmakers Jan AM Koenderman Leo Postma Dirkje S Koppelman Gerard H Maitland-van der Zee Anke Hilse
Publisher: Future Medicine
ISSN: 1462-2416
Source: Pharmacogenomics, Vol.14, Iss.16, 2013-12, pp. : 1965-1971
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Long-acting &bgr;2 agonists: Pfizer’s development candidate?
By Norman Peter
Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 12, 2006-12 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Norman Peter
Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 1, 2006-01 ,pp. :